This is our story in our words.

​

We never intended to tell this story now. We believe in building then talking. We are still building.​

​

We're a small team of engineers and AI and healthcare experts who have witnessed firsthand how present diagnostic systems fail patients and pets alike. We've sat helplessly as family members died from diseases that, detected earlier, might have been treatable. We've experienced heartbreak when veterinarians lack the tools to help the animals that depend on us. These experiences drive our mission. We’re serious people with serious backgrounds, and we’re proud to have the backing of some of the most serious technology investors in the world. ​

​

Current diagnostics focus on measuring discrete biomarkers at isolated moments in time. It's a flawed approach that misses the complex molecular symphony playing out in our bodies. Our technology captures the entire performance: thousands of biomarkers simultaneously, including those science hasn't yet named or understood.

​

AI's transformative potential is constrained by the data it can access. The most valuable companies won't be those with marginally better algorithms or models. They'll be those with proprietary, high-fidelity data sources that others cannot replicate. We are working to build the richest, most comprehensive molecular dataset in healthcare.

​

Our foundation is Raman spectroscopy: a century-old technique with extraordinary potential for diagnosing everything from cancer to neurodegenerative disease that remains confined to the bowels of research labs because the high resolution technology required to enable its most promising applications is prohibitively expensive and complex.

​

Standing on the shoulders of giants, Haemanthus has engineered a pathway to unlock and commercialize this technology by leveraging the billions already invested in LiDAR and Coherent Telecom development—and the trillions invested in AI. Just as LiDAR evolved from million-dollar research systems to standard equipment in some consumer vehicles, we're transforming Raman spectroscopy from lab equipment to an accessible diagnostic platform fueled by AI.

​

We're not building incrementally better tests; we're helping create the foundation for a new understanding of health and disease. We’re creating digital twins of molecular health that will enable AI to realize its full potential in healthcare. We are building the world's first health sensors specifically built for AI.

​

We're starting with veterinary medicine. Not because it's easier, but because it's something we care deeply about and because it is practical. It allows us to validate our technology and help animals who cannot verbalize their symptoms, while building the foundation for potential future human applications. 

​

We were doing our best to keep our heads down and build quietly. We aren't secretive: we have publicly filed our inventions and are committed to transparency. The US Patent and Trademark Office has granted our foundational patents, and we have filed for many more. Our first patent was granted with all 30 claims without office actions. We are early in the process. We’re proud of the progress we have made and the important problems we have solved. 

​

So we’re not in stealth anymore - and so be it. We’ll keep everyone updated when we are ready to. We are willing to work with journalists interested in what we are doing: all we ask is that you are as genuine with us as we are with you. 

​

We are going back to building now. 

​

The Haemanthus Team